TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11355929

Group type: EXPERIMENTAL
Intervention: Combination of all‐trans retinoic acid (ATRA) and conventional anthracycline‐ARA‐C chemotherapy (CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged maintenance treatment with ATRA and low dose CT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapid onset of CT and/or high dose steroids for ATRA syndrome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consolidation CT using an anthracycline alone, without cytarabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allogeneic or autologous stem cell transplantation after ATRA and CT
Number of subjects: 0
Study: 9229600

Group type: EXPERIMENTAL
Intervention: Reversed Tip and Snip
Number of subjects: 30

Group type: COMPARATOR
Intervention: Divide and Conquer
Number of subjects: 30
Study: 7893774

Group type: EXPERIMENTAL
Intervention: Sample case with slight memory complaints
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Sample cases with moderate dementia (vascular dementia and degenerative dementia of Alzheimer type)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Consideration of treatable causes of dementia
Number of subjects: 159
Study: 3107605

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30747758

Group type: EXPERIMENTAL
Intervention: ACES (Accelerated Chest pain Evaluation with Stress imaging)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Usual inpatient care
Number of subjects: 334
Study: 28538556

Group type: EXPERIMENTAL
Intervention: Juvéderm Voluma (2 ml injected)
Number of subjects: 119

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Juvéderm Voluma
Number of subjects: 119
Study: 25939517

Group type: EXPERIMENTAL
Intervention: Acupuncture at seven acupoints bilaterally
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham acupuncture points adjacent to the acupoints
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both acupuncture and sham groups
Number of subjects: 100
Study: 24231251

Group type: EXPERIMENTAL
Intervention: Relative telomere length (RTL) measured by quantitative PCR on blood or buccal cell DNA
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Short RTL (1st tertile) in males
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Short RTL (1st tertile) in females
Number of subjects: 299
Study: 21989182

Group type: EXPERIMENTAL
Intervention: Adjuvant fluorouracil/folinic acid (FU/FA) treatment
Number of subjects: 211

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 211
Study: 19966605

Group type: EXPERIMENTAL
Intervention: Manometric biofeedback plus pelvic floor exercises
Number of subjects: 108

Group type: COMPARATOR
Intervention: Pelvic floor exercises alone
Number of subjects: 108
Study: 17076063

Group type: EXPERIMENTAL
Intervention: Synaesthesia prevalence testing using objective tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grapheme-colour synaesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synaesthesia distribution across sexes
Number of subjects: 0
Study: 15130230

Group type: EXPERIMENTAL
Intervention: Dynamic radioisotope scintigraphy (DRS) using Tc99‐phytate labeled plain yogurt
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional method of fluoroscopic image and barium swallow (FA)
Number of subjects: 40
Study: 11777094

Group type: EXPERIMENTAL
Intervention: Sequential mixed frequency stimulation from a standard device
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: New form of stimulation from an experimental stimulation device with simultaneous mixed frequency components
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 16
Study: 9008249

Group type: EXPERIMENTAL
Intervention: Patient-directed management strategy using home blood pressure monitoring
Number of subjects: 31

Group type: COMPARATOR
Intervention: Office-based management through physician visits
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Patient-directed management
Number of subjects: 31

Group type: COMPARATOR
Intervention: Office-based management
Number of subjects: 31
Study: 8495604

Group type: EXPERIMENTAL
Intervention: 900 mg EPA-E
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1800 mg EPA-E
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (1656 mg olive oil)
Number of subjects: 24
Study: 30537847

Group type: EXPERIMENTAL
Intervention: Analogy instructions (n=19)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Environmental constraints (n=17)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Action observation (n=20)
Number of subjects: 56
Study: 30388160

Group type: EXPERIMENTAL
Intervention: 4 mg DNA-IIV3
Number of subjects: 75

Group type: COMPARATOR
Intervention: IIV3-IIV3
Number of subjects: 75
Study: 27650514

Group type: EXPERIMENTAL
Intervention: Continuous Chest Compressions (CCC)
Number of subjects: 63

Group type: COMPARATOR
Intervention: 30:2 Chest Compressions to Ventilations
Number of subjects: 63
Study: 24317366

Group type: EXPERIMENTAL
Intervention: E+R (epigallocatechin-gallate 282 mg day(‐1) + resveratrol 200 mg day(‐1))
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: E+R+S (epigallocatechin-gallate 282 mg day(‐1) + resveratrol 200 mg day(‐1) + soy isoflavones 80 mg day(‐1))
Number of subjects: 18

Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 18
Study: 22992814

Group type: EXPERIMENTAL
Intervention: Anterior route of injection
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lateral route of injection
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Posterior route of injection
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Posterior route of injection in females
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Posterior route of injection in males
Number of subjects: 75
Study: 20560909

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 1000 μg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluticasone proprionate (FP) 1000 μg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) and Fluticasone proprionate (FP)
Number of subjects: 24
Study: 18633020

Group type: EXPERIMENTAL
Intervention: Intraoperative IV dexamethasone 8 mg and ondansetron 4 mg, followed by 8 mg oral disintegrating ondansetron tablet on discharge and in the morning of postoperative days 1 and 2.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intraoperative IV ondansetron 4 mg (control group).
Number of subjects: 60
Study: 15863529

Group type: EXPERIMENTAL
Intervention: Testosterone patch (300 mug/d)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 533
Study: 11844962

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients (CF)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Non-CF controls (healthy individuals and individuals with acute cold)
Number of subjects: 54
Study: 9918281

Group type: EXPERIMENTAL
Intervention: Carbomix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Actidose‐Aqua
Number of subjects: 0
Study: 7570788

Group type: EXPERIMENTAL
Intervention: Assessment plus 1-semester experimental program
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Assessment plus 2-semester experimental program
Number of subjects: 105

Group type: COMPARATOR
Intervention: Assessment-only group
Number of subjects: 105
Study: 2405109

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 75 mg/m2 and doxorubicin (Dox) 50 mg/m2 intravenously every 3 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) and doxorubicin (Dox) as neoadjuvant therapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) and doxorubicin (Dox) as sole therapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Multimodality therapy (CT followed by surgery or radiation therapy)
Number of subjects: 28
Study: 7437258

Group type: EXPERIMENTAL
Intervention: Prolintane (15 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prolintane (30 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pemoline (60 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pemoline (100 mg)
Number of subjects: 6
Study: 30388242

Group type: EXPERIMENTAL
Intervention: Supplemental protein feeding (four commercially available protein supplements, wildflower pollen supplement)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Negative control (no supplemental protein)
Number of subjects: 75
Study: 30012122

Group type: EXPERIMENTAL
Intervention: Guideline implementation strategies including patient education booklet, online cancer pain education module, audit and feedback
Number of subjects: 492

Group type: COMPARATOR
Intervention: Routine screening for average and worst pain using a 0-10 NRS and access to online guidelines
Number of subjects: 492
Study: 28053985

Group type: EXPERIMENTAL
Intervention: Physical-cognitive dual task (DT) training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Physical single task (ST) training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups (DT and ST)
Number of subjects: 36
Study: 25281275

Group type: EXPERIMENTAL
Intervention: Rhythm control strategy (including electrical cardioversion and pharmacotherapy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rate control strategy
Number of subjects: 60
Study: 22305837

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 1,000 U/kg intravenously immediately after reperfusion
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control (standard care alone)
Number of subjects: 110
Study: 20571180

Group type: EXPERIMENTAL
Intervention: Eszopiclone co-administered with fluoxetine (ESZ+FLX)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Placebo co-administered with fluoxetine (PBO+FLX)
Number of subjects: 434
Study: 17505681

Group type: EXPERIMENTAL
Intervention: 21-week exercise group (n = 10), low to moderate intensity, 60 minutes, 2 days/week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 20
Study: 15763646

Group type: EXPERIMENTAL
Intervention: Soy capsules
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 11965273

Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 592

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 592
Study: 9798453

Group type: EXPERIMENTAL
Intervention: Mupirocin nasal ointment
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 1044
Study: 7674691

Group type: EXPERIMENTAL
Intervention: Early intervention in heart failure
Number of subjects: 0
Study: 2678162

Group type: EXPERIMENTAL
Intervention: VALERINA NATT (valerian preparation)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 301629

Group type: EXPERIMENTAL
Intervention: 100 microgram of vitamin D2
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 100 microgram of 25 hydroxyvitamin D3
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 100 microgram of 5,6 trans‐25 hydroxyvitamin D3
Number of subjects: 21
Study: 31849040

Group type: EXPERIMENTAL
Intervention: Inspiratory oxygen fraction of 0.80 and intravenous bolus of vitamin C and infusion of N-acetylcysteine
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Inspiratory oxygen fraction of 0.30 and intravenous bolus of vitamin C and infusion of N-acetylcysteine
Number of subjects: 600

Group type: COMPARATOR
Intervention: Inspiratory oxygen fraction of 0.80 and matching placebo
Number of subjects: 600

Group type: COMPARATOR
Intervention: Inspiratory oxygen fraction of 0.30 and matching placebo
Number of subjects: 600
Study: 31062459

Group type: EXPERIMENTAL
Intervention: Radiomics signature
Number of subjects: 210
Study: 28993130

Group type: EXPERIMENTAL
Intervention: Gait retraining intervention (6-week program of increasing cadence and use of a minimalist shoe)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Foot orthoses (prefabricated)
Number of subjects: 16
Study: 26705095

Group type: EXPERIMENTAL
Intervention: Traditional counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-centered counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-centered counseling with audio reinforcement
Number of subjects: 0
Study: 24635002

Group type: EXPERIMENTAL
Intervention: Short-term Psychoanalytic Child Therapy (PaCT), 20-25 sessions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Short-term Psychoanalytic Child Therapy (PaCT)
Number of subjects: 30
Study: 22158101

Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Number of subjects: 18
Study: 20477768

Group type: EXPERIMENTAL
Intervention: Kessler's K6 psychological distress scale
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Kessler's K10 psychological distress scale
Number of subjects: 71

Group type: COMPARATOR
Intervention: Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Hamilton Depression Rating Scale (HDRS)
Number of subjects: 71
Study: 18083471

Group type: EXPERIMENTAL
Intervention: 8 mg lornoxicam infusion 30 minutes before skin incision
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline infusion immediately after skin closure (control group)
Number of subjects: 44
Study: 16128938

Group type: EXPERIMENTAL
Intervention: Tenatoprazole 40 mg once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 30
Study: 14585672

Group type: EXPERIMENTAL
Intervention: New TBE vaccine
Number of subjects: 222

Group type: COMPARATOR
Intervention: Formerly licensed TBE vaccine
Number of subjects: 222
Study: 10554902

Group type: EXPERIMENTAL
Intervention: Acarbose with IMI of 0 min
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo with IMI of 30 min
Number of subjects: 15
Study: 9076651

Group type: EXPERIMENTAL
Intervention: Methadone formulation change
Number of subjects: 177
Study: 1725029

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 6205336

Group type: EXPERIMENTAL
Intervention: salm-calcitonin and polychemo-therapy or hormonal treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no calcitonin therapy)
Number of subjects: 48
Study: 30694881

Group type: EXPERIMENTAL
Intervention: Milk thistle (150 mg to 300 mg twice a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Milk thistle
Number of subjects: 20
Study: 28343976

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (25 Gy in ten daily fractions of 2·5 Gy)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Number of subjects: 224
Study: 26536022

Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine (1-6 mg per dose, mean 3.4 mg) administered 3 times at 2-hour intervals
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 23632348

Group type: EXPERIMENTAL
Intervention: Patient-based Harvey Bradshaw Index (P-HBI)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Clinician-based Harvey Bradshaw Index (HBI)
Number of subjects: 181
Study: 21233014

Group type: EXPERIMENTAL
Intervention: TPF (docetaxel 75 mg/m², cisplatin 100 mg/m², fluorouracil 1000 mg/m² for 4 days)
Number of subjects: 501

Group type: COMPARATOR
Intervention: PF (cisplatin 100 mg/m², fluorouracil 1000 mg/m² for 5 days)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: TPF
Number of subjects: 501

Group type: COMPARATOR
Intervention: PF
Number of subjects: 501
Study: 19225296

Group type: EXPERIMENTAL
Intervention: Statins (specific type not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no statin therapy)
Number of subjects: 0
Study: 17694201

Group type: EXPERIMENTAL
Intervention: Concise (3M Espe) sealant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prisma Shield (Caulk/Dentsply) sealant
Number of subjects: 0
Study: 15389416

Group type: EXPERIMENTAL
Intervention: Low-energy-dense salad (0.33 kcal/g) small portion (150 g)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low-energy-dense salad (0.33 kcal/g) large portion (300 g)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High-energy-dense salad (1.33 kcal/g) small portion (150 g)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High-energy-dense salad (1.33 kcal/g) large portion (300 g)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Large portion of lower-energy-dense salad (compared to a high-energy-dense salad with the same calories)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No salad (control condition)
Number of subjects: 42
Study: 12090907

Group type: EXPERIMENTAL
Intervention: Fosinopril monotherapy (20 mg daily for 30 months)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Hydrochlorothiazide and hydralazine combination
Number of subjects: 66
Study: 9520174

Group type: EXPERIMENTAL
Intervention: COL‐1492 gel
Number of subjects: 534

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 534

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 534
Study: 8061724

Group type: EXPERIMENTAL
Intervention: Glucose infusion (11.1 mumol/kg/min) + Amino acids infusion (3.33 mg/kg/min for last 4 hours)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glucose infusion (11.1 mumol/kg/min) + Lipids infusion (Lipovenös, 10% 10 ml/min for 7.5 h) + Amino acids infusion (for last 4 hours)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glucose infusion (11.1 mumol/kg/min) + Lipids infusion (10% 10 ml/min) + Amino acids infusion (for last 4 hours)
Number of subjects: 10
Study: 2509153

Group type: EXPERIMENTAL
Intervention: T2 (polyglycosides of Tripterygium wilfodii hook F)
Number of subjects: 70
Study: 959765

Group type: EXPERIMENTAL
Intervention: Jejunal acidification
Number of subjects: 18

Group type: COMPARATOR
Intervention: Exogenous hormones (secretin and CCK)
Number of subjects: 18
Study: 31982359

Group type: EXPERIMENTAL
Intervention: 150 mg pregabalin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 75 mg pregabalin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 31288827

Group type: EXPERIMENTAL
Intervention: Bipolar coagulation
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Laparoscopic suture
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Hemostatic matrix
Number of subjects: 84
Study: 28719287

Group type: EXPERIMENTAL
Intervention: DPIV formulations (1 or 4 μg with aluminum hydroxide or 1 μg with AS01E or AS03B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DPIV formulations
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100
Study: 26553086

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg/PO/bed time)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 24119468

Group type: EXPERIMENTAL
Intervention: FIR-radiated therapy (40-minute radiation at the major lesion site or anastomosed site three times a week)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (free-radiated usual therapy)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: FIR-radiated therapy
Number of subjects: 216
Study: 21504407

Group type: EXPERIMENTAL
Intervention: Functional Walking Test (FWT)
Number of subjects: 56
Study: 19793367

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (group I, n = 32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (group II, n = 32)
Number of subjects: 64
Study: 17526179

Group type: EXPERIMENTAL
Intervention: Acupoint drug-finger pressing (ADFP) on Ganshu (BL18), Danshu (BL19), Weishu (BL21), and Pishu (BL20) acupoints, 15 min each time, twice per day for 3 weeks.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Acid-inhibitory and gastrokinetic drugs (omeprazole 20 mg once every 12 hours and cisapride 10 mg thrice daily before meals) for 3 weeks.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (ADFP and control)
Number of subjects: 80
Study: 15513716

Group type: EXPERIMENTAL
Intervention: Key size of 20 mm
Number of subjects: 20

Group type: COMPARATOR
Intervention: Key sizes of 10, 15 mm
Number of subjects: 20

Group type: COMPARATOR
Intervention: Key size of 25 mm
Number of subjects: 20
Study: 11487144

Group type: EXPERIMENTAL
Intervention: 15% EDTA/NaOCl
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 10% polyacrylic acid
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 35% phosphoric acid
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 6% citric acid
Number of subjects: 50

Group type: COMPARATOR
Intervention: 5.25% NaOCl
Number of subjects: 50
Study: 9663911

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring for 2 weeks (6 work days, duplicate measurements, twice daily)
Number of subjects: 189
Study: 7893593

Group type: EXPERIMENTAL
Intervention: Supine bicycle ergometry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta 1-adrenoceptor antagonism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ergometric rise of HR
Number of subjects: 0
Study: 2316416

Group type: EXPERIMENTAL
Intervention: Nonalcoholic beer
Number of subjects: 0
Study: 334490

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 48

Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 48
Study: 31876052

Group type: EXPERIMENTAL
Intervention: 40 mg Echinacea angustifolia root extract twice daily for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo tablets twice daily for 7 days
Number of subjects: 0
Study: 31389880

Group type: EXPERIMENTAL
Intervention: Hand surgery (carpal tunnel release, trigger finger release, ganglion or retinacular cyst excision, de Quervain's release, or soft‐tissue mass excision)
Number of subjects: 430965

Group type: EXPERIMENTAL
Intervention: Surgical antibiotic prophylaxis before hand surgery
Number of subjects: 430965

Group type: COMPARATOR
Intervention: Control group (no hand surgery)
Number of subjects: 430965
Study: 28100522

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 5499
Study: 25045795

Group type: EXPERIMENTAL
Intervention: Cathejell lubricant with lidocaine 12.5g administered immediately before cystoscopy
Number of subjects: 242

Group type: COMPARATOR
Intervention: Cathejell lubricant with lidocaine 12.5g maintained for 5 minutes before cystoscopy
Number of subjects: 242
Study: 22580433

Group type: EXPERIMENTAL
Intervention: Electrocautery pen (ECP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nylon 10‐0 sutures
Number of subjects: 80